Abstract: The present disclosure is directed to individual A? peptide immunogen constructs, peptide compositions comprising these A? peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these A? peptide immunogen constructs, with the individual A? peptide immunogen constructs having the N-terminus of the A? peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the A? peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease.

Abstract: The present invention is directed to novel heterologous promiscuous and artificial T helper cell epitopes (Th epitopes) designed to provide optimum immunogenicity of a target antigenic site. The disclosed Th epitopes, when covalently linked to a B cell epitope in a peptide immunogen construct, elicit a strong antibody response to the B cell epitope of the target antigenic site. The Th epitopes are immunosilent on their own, i.e., little, if any, of the antibodies generated by the peptide immunogen constructs will be directed towards the Th epitope, thus allowing a very focused immune response directed to the targeted antigenic site. The heterologous promiscuous Th epitopes provide effective and safe peptide immunogens that do not generate inflammatory, anti-self, cell-mediated immune responses following administration.

Abstract: The present disclosure is directed to antibodies directed against CD4, compositions thereof, and methods employing such compositions for the prevention, treatment, and/or functional cure of HIV infection. The disclosed antibodies exert potent competitive HIV entry inhibition by binding to domain 1 of CD4 in both cell-free and cell-to-cell systems. The disclosed antibodies also inhibit antigen induced T cell proliferation and cytokine production (IL2 and IFN-gamma) of CD4+ T cells, which is implicated in the pathogenic cycle of pyroptosis. The disclosed antibodies also have the ability to reactivate resting CD4+ T cells, which is particularly useful for reactivating latent reservoirs of HIV in resting T cells to make these cells susceptible to treatment with antiretroviral agents. Reactivation of HIV infected resting CD4+ T cells allows combinational treatment incorporating antibodies of the current invention with HAART in HIV infected patients leading to the functional cure of HIV.

Abstract: The present disclosure is directed to dipeptide repeat (DPR) peptide immunogen constructs, compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed DPR peptide immunogen constructs contain a B cell epitope derived from a DPR protein from C9orf72, including repeats of poly-GA, poly-GP, poly-GR, poly-PR, and poly-PA, linked to a heterologous T helper cell (Th) epitope directly or through an optional heterologous spacer. The B cell epitope portion of the peptide immunogen constructs contain about 10 to about 25 repeats of the respective dipeptide sequence. The disclosed peptide immunogen constructs stimulate the generation of highly specific antibodies directed against the DPR sequences.

Abstract: The present invention is to determine whether a game result of a slot machine satisfies a specified condition by using a control unit, the specified condition is defined as any one of the plurality of game symbols in the game result replaced so that the reward condition is satisfied, and one of the game symbols replaced to be located at a replacement position; when the control unit determines that the game result satisfies the specified condition, the control unit activates a three-dimensional re-spinning component to generate a replacement game symbol. The replacement game symbol is used to replace the game symbol at the replacement position and update the game result, thereby the control unit re-determines whether the updated game result meets the reward condition, and after the reward condition is met, performs a reward program by using a reward unit.

Abstract: The present disclosure is directed to alpha-synuclein (?-Syn) peptide immunogen constructs, compositions containing the constructs, antibodies elicited by the constructs, and methods for making and using the constructs and compositions thereof. The disclosed ?-Syn peptide immunogen constructs contain a B cell epitope from ?-Syn linked to a heterologous T helper cell (Th) epitope directly or through an optional heterologous spacer. The B cell epitope portion of the peptide immunogen constructs contain about 10 to about 25 amino acid residues of ?-Syn, corresponding to the sequence from about the Glycine at position 111 (G111) to about the Asparagine at position 135 (D135) of full-length ?-Syn. The ?-Syn peptide immunogen constructs stimulate the generation of highly specific antibodies that are cross-reactive with the ?-sheet of ?-Syn as monomers, oligomers, and fibrils, but not the natural ?-helix of ?-Syn, offering therapeutic immune responses to hosts at risk for synucleinopathies.

Abstract: The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Tau protein for the treatment and/or prevention of tauopathies. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs.

Abstract: The present disclosure is directed to individual peptide immunogen constructs targeting portions of the Interleukin-31 (IL-31) protein for the treatment and/or prevention of a pruritic condition and/or an allergic condition, such as atopic dermatitis. The present disclosure is also directed to compositions containing the peptide immunogen constructs, methods of making and using the peptide immunogen constructs, and antibodies produced by the peptide immunogen constructs.

Abstract: The present invention relates to a game system allowing at least one prize money value to correspond to at least one optional betting option respectively. After a player bets on the at least one optional betting option, the at least one prize money value corresponding to the at least one optional betting option that has been betted may be activated, such that the player has an opportunity to obtain the at least one prize money value that has been activated. Therefore, the game system of the present invention can induce the player to bet on the optional betting option by virtue of the presence and display of the prize money values, as well as the player's desire to obtain the prize money values, thereby increasing the willingness of the player to raise bets and the revenue of the game system.

Abstract: The present invention is to determine whether a game result of a slot machine satisfies a specified condition by using a control unit, the specified condition is defined as any one of the plurality of game symbols in the game result replaced so that the reward condition is satisfied, and one of the game symbols replaced to be located at a replacement position; when the control unit determines that the game result satisfies the specified condition, the control unit activates a three-dimensional re-spinning component to generate a replacement game symbol. The replacement game symbol is used to replace the game symbol at the replacement position and update the game result, thereby the control unit re-determines whether the updated game result meets the reward condition, and after the reward condition is met, performs a reward program by using a reward unit.

Abstract: The present invention relates to a game system allowing at least one prize money value to correspond to at least one optional betting option respectively. After a player bets on the at least one optional betting option, the at least one prize money value corresponding to the at least one optional betting option that has been betted may be activated, such that the player has an opportunity to obtain the at least one prize money value that has been activated. Therefore, the game system of the present invention can induce the player to bet on the optional betting option by virtue of the presence and display of the prize money values, as well as the player's desire to obtain the prize money values, thereby increasing the willingness of the player to raise bets and the revenue of the game system.

Abstract: The present invention mainly includes a score determination unit determining whether a game score of a player satisfies a score threshold value and accordingly generating a score determination signal. A processing unit determines whether to enable an additional bet option according to the score determination signal, and then the processing unit controls a game status display unit to display an enabled status of the additional bet option. When the additional bet option is in the enabled status, the player selects to bet to generate an additional bet signal, and the processing unit controls an odds generation unit to generate at least one of additional random odds. Therefore, the player obtains payouts of the additional random odds.

Abstract: A vaccine composition for castrating pigs, comprising a peptide immunogen and a veterinarily acceptable delivery vehicle or adjuvant, wherein the peptide immunogen comprises (a) a LHRH peptide of SEQ ID NO: 1, and (b) at least one T helper epitope selected from a group consisting of SEQ ID NOs: 2, 3, 4, and 5, and, optionally, an immunostimulatory peptide of SEQ IN NO: 6, wherein the LHRH peptide is covalently linked through its N-terminus residue to the T helper epitope or immunostimulatory peptide. A method for castrating or inhibiting characteristics, including boar taint, induced by the sexual maturation of pigs using the vaccine composition is also disclosed.

Abstract: A gaining device includes a prize pool switch control system, which includes an activation threshold calculating element and a control computing unit. The activation threshold calculating element generates at least one activation threshold according to a betting selection of a player and a designated computation method. The control computing unit performs a procedure of: a) capturing the at least one activation threshold and a plurality of prize money values of a prize money server device; b) comparing the prize money values with the at least one activation threshold, and generating an activation signal when at least one of the prize money values corresponds to the at least one activation signal; and c) transmitting the activation signal to the prize money server device to cause a prize money award of the prize money value corresponding to the at least one activation threshold to be in a triggerable state.

Abstract: Synthetic FMD peptide immunogens and compositions containing the same are disclosed. Methods for detecting, treating, and preventing an FMD infection in an animal using the synthetic FMD peptide immunogens are also disclosed. In a specific embodiment, a peptide-based emergency vaccine and formulations thereof against Foot and Mouth Disease is described. Various vaccine formulations contain a mixture of peptides derived from FMDV VP1 protein; each peptide containing a B cell FMDV neutralizing/receptor binding epitope sequence linked to an artificial Th epitope to enhance the immunogenicity of each peptide. Disclosed vaccine formulations containing viral immunogens can optionally be supplemented with a mixture of peptides representing the FMDV endogenous Th epitopes derived from FMDV proteins, homologues and functional analogues thereof.

Abstract: The present disclosure is directed to compositions and methods for the prevention, treatment, and/or functional cure of HIV infection. One aspect of the present disclosure relates to monoclonal antibodies directed against CD4, compositions thereof, and methods employing such compositions for the prevention, treatment, and functional cure of HIV infection.

Abstract: The present disclosure is directed to individual A? peptide immunogen constructs, peptide compositions comprising these A? peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these A? peptide immunogen constructs, with the individual A? peptide immunogen constructs having the N-terminus of the A? peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the A? peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease.

Abstract: A peptide-based marker vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS) and a set of immunodiagnostic tests for the prevention, monitoring and control of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) are disclosed. Vaccine formulations according to various embodiments of the invention contain a mixture of peptides derived from PRRSV GP2, GP3, GP4, or GP5 proteins; each peptide individually contains a B cell PRRSV neutralizing/receptor binding epitope which is individually linked to an artificial T helper epitope for enhancement of the respective peptide's immunogenicity; and which can be supplemented with a mixture of peptides representing the T helper epitopes derived from the PRRSV GP4, GP5, M and Nucleocapsid proteins to provide cell mediated immunity. Such viral peptide compositions are prepared in an acceptable delivery system as vaccine formulations and can provide cross protection of PRRSV antibody free pigs from infection upon PRRSV challenge.

Abstract: The present disclosure is directed to individual A? peptide immunogen constructs, peptide compositions comprising these A? peptide immunogen constructs and mixtures thereof, pharmaceutical compositions including vaccine formulations comprising these A? peptide immunogen constructs, with the individual A? peptide immunogen constructs having the N-terminus of the A? peptide as the B cell (B) epitopes linked through spacer residue(s) to heterologous T helper cell (Th) epitopes derived from pathogen proteins that act together to stimulate the generation of highly specific antibodies directed against the N-terminus of the A? peptide offering protective immune responses to patients at risk for, or with, Alzheimer's Disease.

Abstract: Porcine circovirus (PCV2) vaccine compositions comprising a peptide antigen derived from a PCV2 capsid protein are described. In various embodiments, the peptide antigen contains amino acids of the capsid protein from about amino acid 47 to about amino acid 202. In some embodiments, the peptide antigen is optionally linked to an artificial T helper epitope and/or mixed with T helper epitopes derived from the ORF1 and ORF3 proteins of PCV2. Methods of using PCV2 vaccine compositions are also described. In various embodiments, a vaccine composition is used in animals for the prevention of PCV2 infection. In other embodiments, a PCV2 vaccine composition is used as an antigen for diagnosing PCV2 infection.